Axsome Therapeutics (NASDAQ: AXSM) reported Q1 EPS of ($1.22), $0.08 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $121.46 million versus the consensus estimate of $121.58 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.